Mechanisms of Resistance and Synergy: The Role of Tumor Microenvironment in HER2-Low Breast Cancer Therapy

HER2-low breast cancer, also known as IHC 1+ or IHC 2+ without ERBB2 amplification, is a new concept in the biology of breast cancer that has removed the binary classification of HER2-positive or HER2-negative breast cancer. The recent introduction of antibody-drug conjugates (ADCs), such as trastuz...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Youssef Basem, Alamer Ata, Abanoub Sherif, Shaimaa Abdel-Ghany, Borros Arneth, Hussein Sabit
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2026-03-01
Edice:	Pharmaceuticals
Témata:	HER2-low breast cancer tumor microenvironment antibody–drug conjugates trastuzumab deruxtecan drug resistance
On-line přístup:	https://www.mdpi.com/1424-8247/19/4/541
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!